Frequent Dosing of Topical Cyclosporine A for Severe Ocular Surface Disease

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Anisa I GireEsen Karamursel Akpek

Abstract

To study the systemic safety and patient tolerability of frequent dosing of cyclosporine A (CsA) 0.05% eyedrops in the treatment of ocular surface disease. This is a retrospective case series. Patients with significant ocular surface diseases who were treated using topical CsA higher than the usual twice daily dosing (3-8 times daily and over a treatment period of 1-70 months). The main outcome measures are plasma levels of CsA and local tolerability. Symptom assessment, corneal staining using fluorescein, conjunctival staining using lissamine green, tear film breakup time, and other signs according to the disease process were monitored. Discontinuation of treatment due to intolerability was recorded. CsA levels were measured in the plasma at a clinical laboratory. Plasma levels of CsA were below the level of detection (7 ng/mL) in all the 41 patients included. All patients tolerated the treatment well with none discontinuing due to any treatment-related local adverse effects. This study demonstrates that CsA 0.05% ophthalmic emulsion applied more frequently than the usual twice daily dosing was safe and well tolerated in patients with significant ocular surface diseases.

References

Nov 1, 1986·Survey of Ophthalmology·R B Nussenblatt, A G Palestine
Aug 1, 1985·Klinische Monatsblätter für Augenheilkunde·F Hoffmann, M Wiederholt
Jan 1, 1993·International Ophthalmology Clinics·M D de Smet, R B Nussenblatt
Jan 1, 1996·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·R G FiscellaS Labib
Sep 25, 2002·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Neri PucciAlberto Vierucci
Nov 7, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·David S SmallDiane D-S Tang-Liu
Oct 31, 2003·Expert Reviews in Molecular Medicine·S M Stepkowski
Oct 27, 2004·Cornea·Prabashni ReddyKrithika Rajagopalan
Sep 20, 2005·The British Journal of Ophthalmology·S Tatlipinar, E K Akpek
Oct 25, 2006·International Ophthalmology Clinics·Gary N Foulks
Jan 4, 2008·Expert Opinion on Drug Safety·Shahram Kashani, Ali A Mearza
Feb 13, 2009·American Journal of Ophthalmology·Anita GuptaEsen Karamursel Akpek
May 9, 2009·Survey of Ophthalmology·Eric Donnenfeld, Stephen C Pflugfelder
Aug 26, 2010·Ocular Immunology and Inflammation·Canan Asli UtineEsen K Akpek
Sep 18, 2010·Cornea·João Baptista MaltaShahzad I Mian
Aug 1, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Meng XinXianggen Wu
May 28, 2013·Current Ophthalmology Reports·Miki Uchino, Debra A Schaumberg
Oct 15, 2013·The British Journal of Ophthalmology·Suzanne W van LandinghamPradeep Y Ramulu
Jan 7, 2014·American Journal of Ophthalmology·Adam J PaulsenDayna S Dalton
Oct 31, 2014·Cornea·Mohammed Ziaei, Bita Manzouri

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.